Finance

Lists
Outlook: 75.0% bullish·8.3% bearish
Go to analysis
HRMY:NASDAQ
Harmony Biosciences Holdings Inc
$33.11
+1.97%
(+0.64) 1D
$33.00
-0.33% (-0.11)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HRMY...
Open
$32.70
High
$33.38
Low
$32.27
Mkt. cap
1.93B
Avg. vol.
1.08M
Volume
787.17K
P/E ratio
10.92
52-wk high
$43.49
52-wk low
$25.90
EPS
$3.03
Beta
1.00
Shares outstanding
58.72M
No. of employees
293
Open
$32.70
High
$33.38
Low
$32.27
Mkt. cap
1.93B
Avg. vol.
1.08M
Volume
787.17K
P/E ratio
10.92
52-wk high
$43.49
52-wk low
$25.90
EPS
$3.03
Beta
1.00
Shares outstanding
58.72M
No. of employees
293
News stories
From web sources and news partners
About Harmony Biosciences Holdings Inc
CEO-
Employees293
Founded2017
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 8 analysts giving stock ratings to HRMY in the past 3 months
Buy
Buy
5
Hold
2
Sell
1
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for HRMY in the last 3 months.
Highest
Current $33.11
$60.00 (+81.21%)
Average
$47.50 (+43.46%)
Lowest
$30.00 (-9.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
So Youn Shim
UBS
Hold
Maintained
$39.00
+17.8%
11/06/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$55.00
+66.1%
11/05/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$49.00
+48%
10/29/2026
Ami Fadia
Needham
Buy
Reiterated
$50.00
+51%
10/19/2026
Caroline Palomeque
Ladenburg Thalmann & Co.
Buy
Initiated
$55.00
+66.1%
10/15/2026
Jason Gerberry
Bank of America Securities
Sell
Maintained
$30.00
-9.4%
10/12/2026
David Hoang
Deutsche Bank
Hold
Maintained
$42.00
+26.8%
10/01/2026
Rudy Li
Wolfe Research
Buy
Initiated
$60.00
+81.2%
08/26/2026
Danielle Brill
Truist Financial
Hold
Maintained
$34.00
+2.7%
08/05/2026
Corinne Johnson
Goldman Sachs
Hold
Maintained
$37.00
+11.7%
07/16/2026
Jay Olson
Oppenheimer
Buy
Maintained
$72.00
+117.5%
04/22/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$46.00
+38.9%
04/22/2026
Andreas Argyrides
Oppenheimer
Buy
Reiterated
$62.00
+87.3%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
243.78M
215.39M
261.28M
268.92M
Cost of goods sold
68.54M
44.51M
63.20M
80.69M
Cost of revenue
68.54M
44.51M
63.20M
80.69M
Research and development expenses
49.93M
69.38M
46.60M
71.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
86.74M
64.20M
62.17M
62.37M
Operating expense
136.67M
133.58M
108.77M
134.03M
Total operating expenses
205.22M
178.10M
171.96M
214.72M
Operating income
38.56M
37.29M
89.32M
54.20M
Other non operating income
-105.00K
-127.00K
-53.00K
-316.00K
EBT including unusual items
40.76M
39.69M
93.26M
59.25M
EBT excluding unusual items
40.76M
39.69M
93.26M
59.25M
Income tax expense
18.27M
7.20M
17.83M
11.05M
Effective tax rate
44.83%
18.14%
19.12%
18.66%
Other operating expenses
-
-
-
-
Net income
22.49M
32.49M
75.43M
48.20M
Net profit margin
9.22%
15.08%
28.87%
17.92%
Earnings per share
0.57
0.79
1.50
-
Interest and investment income
5.85M
5.76M
7.07M
8.43M
Interest expense
-3.55M
-3.23M
-3.07M
-3.06M
Net interest expenses
2.31M
2.52M
4.00M
5.37M
Depreciation and amortization charges
-
-
-
-
EBITDA
45.99M
43.26M
95.28M
60.16M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps